madman
Super Moderator
* Key discussions include the safety and efficacy of low-dose local vaginal estrogen, the importance of a patient-centered, shared decision-making approach, and clear consensus on when to use various therapies.
The new interdisciplinary guidelines for the Genitourinary Syndrome of Menopause (GSM) represent a critical, evidence-based advancement in women's health. Host Rachel S. Rubin, MD, is joined by co-chairs Melissa Kaufman, MD, PhD, and Una Lee, MD, to discuss the impact, scope, and key recommendations of this landmark document.
This video breaks down why all providers, from primary care to specialists, must be aware of these consensus statements to improve patient outcomes. Learn about the multi-society collaboration—including the American Urological Association (AUA) and others—that resulted in these pragmatic statements for GSM treatment. The experts define GSM as a constellation of genital and urinary symptoms caused by decreased estrogen, highlighting how it affects a broader spectrum of patients, including those on oral contraceptives or undergoing cancer treatment. Key discussions include the safety and efficacy of low-dose local vaginal estrogen, the importance of a patient-centered, shared decision-making approach, and clear consensus on when to use various therapies. This initiative is designed to be transformative, empowering clinicians with the knowledge to offer effective, safe, and easily implemented solutions for this common, yet often undertreated, condition.
Chapters
00:00 - Introduction to New GSM Guidelines
00:44 - Introducing the Co-Chairs: Melissa Kaufman, MD, PhD & Una Lee, MD
01:14 - Endorsing Organizations and Collaborative Effort
01:40 - Defining the Genitourinary Syndrome of Menopause (GSM)
02:36 - Who Does GSM Affect? Expanding Beyond Menopause
04:09 - Shared Decision Making and Patient-Centered Care
05:07 - The GSM Treatment Toolbox: Local Hormonal Therapies
06:10 - Addressing Safety and Misconceptions of Vaginal Estrogen
06:57 - Consensus on Laser Therapies for GSM
08:29 - Key Takeaways and Transformative Impact on Women's Health
The new interdisciplinary guidelines for the Genitourinary Syndrome of Menopause (GSM) represent a critical, evidence-based advancement in women's health. Host Rachel S. Rubin, MD, is joined by co-chairs Melissa Kaufman, MD, PhD, and Una Lee, MD, to discuss the impact, scope, and key recommendations of this landmark document.
This video breaks down why all providers, from primary care to specialists, must be aware of these consensus statements to improve patient outcomes. Learn about the multi-society collaboration—including the American Urological Association (AUA) and others—that resulted in these pragmatic statements for GSM treatment. The experts define GSM as a constellation of genital and urinary symptoms caused by decreased estrogen, highlighting how it affects a broader spectrum of patients, including those on oral contraceptives or undergoing cancer treatment. Key discussions include the safety and efficacy of low-dose local vaginal estrogen, the importance of a patient-centered, shared decision-making approach, and clear consensus on when to use various therapies. This initiative is designed to be transformative, empowering clinicians with the knowledge to offer effective, safe, and easily implemented solutions for this common, yet often undertreated, condition.
Chapters
00:00 - Introduction to New GSM Guidelines
00:44 - Introducing the Co-Chairs: Melissa Kaufman, MD, PhD & Una Lee, MD
01:14 - Endorsing Organizations and Collaborative Effort
01:40 - Defining the Genitourinary Syndrome of Menopause (GSM)
02:36 - Who Does GSM Affect? Expanding Beyond Menopause
04:09 - Shared Decision Making and Patient-Centered Care
05:07 - The GSM Treatment Toolbox: Local Hormonal Therapies
06:10 - Addressing Safety and Misconceptions of Vaginal Estrogen
06:57 - Consensus on Laser Therapies for GSM
08:29 - Key Takeaways and Transformative Impact on Women's Health
